Olaf Degen

Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study

Alison Rodger, Valentina Cambiano, Tina Bruun et al. · The Lancet · 2019 · 998 citations · Full text

Public Health, Infectious Disease Control, Preventive Medicine +17

Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study

Chloe Orkin, Shinichi Oka, Patrick Philibert et al. · The Lancet HIV · 2021 · 177 citations

Pharmacy, Pharmacology, Pharmacotherapy +17

Comprehensive Analysis of Frequency and Phenotype of T Regulatory Cells in HIV Infection: CD39 Expression of FoxP3⁺T Regulatory Cells Correlates with Progressive Disease

Julian Schulze zur Wiesch, Adriana Thomssen, Philip Hartjen et al. · Journal of Virology · 2010 · 170 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

Josep M. Llibre, Carlos Brites, Chien‐Yu Cheng et al. · Clinical Infectious Diseases · 2022 · 170 citations · Full text

Pharmacy, Pharmacotherapy, Clinical Pharmacology +15

Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy

Helmut Albrecht, Christian Hoffmann, Olaf Degen et al. · AIDS · 1998 · 151 citations

Medicine, Infectious Diseases, Pharmacology +12